ストックスクリーナーアプリを入手
4.59
2.00%
0.09
前日終値:
$4.50
開ける：
$4.53
24時間の取引高:
853.94K
Relative Volume:
0.54
時価総額：
$429.20M
収益：
$824.50M
当期純損益:
$-365.90M
株価収益率:
-1.1611
EPS:
-3.9531
ネットキャッシュフロー:
$-25.60M
1週間 パフォーマンス:
-1.92%
1か月 パフォーマンス:
-0.43%
6か月 パフォーマンス:
-40.62%
1年 パフォーマンス:
-48.08%
1日の値動き範囲:
$4.51
$4.695
1週間の範囲:
$4.20
$4.81
52週間の値動き範囲:
$3.76
$8.97
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.59 | 420.79M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 183.71B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 135.02B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.85B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.37B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - natlawreview.com
Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P Composite 1500 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 Health Care - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000 - marketscreener.com
If You Invested $1,000 in Myriad Genetics (MYGN) - Stock Titan
Gene Patent Showdown For Myriad Comes to a Head - Yahoo
MYGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN
Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - za.investing.com
FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - GuruFocus
Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times
Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn
Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan
Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan
Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan
Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan
Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan
Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan
Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan
Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS
Myriad Genetics, Inc. $MYGN Shares Sold by Anson Funds Management LP - MarketBeat
Market Review: Is now the right time to enter Myriad Genetics Inc2026 Selloffs & Accurate Intraday Trading Signals - baoquankhu1.vn
3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - Finviz
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge - GuruFocus
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock - MarketBeat
Raha, Myriad Genetics CEO, buys $199k in shares By Investing.com - Investing.com South Africa
Raha, Myriad Genetics CEO, buys $199k in shares - Investing.com Nigeria
Trading Systems Reacting to (MYGN) Volatility - Stock Traders Daily
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript - MSN
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
大文字化:
|
ボリューム (24 時間):